Due to its characteristic aberrant glycosylation as a result of reduced activity of glycosyltransferases and accelerated activity of sialyltransferases in the MUC1 biosynthesis in breast cancer cells 12, breast-(TA)MUC1 represents a tumor-specific marker and target for therapy 13. This evidence concerns the gene MUC1 and neoplasm.